NEW YORK (GenomeWeb) – Researchers from Mount Sinai School of Medicine, along with collaborators from Alnylam Pharmaceuticals, reported this week new animal data showing that RNAi can be used to prevent and treat the neurovisceral attacks that characterize acute intermittent porphyria (AIP).

The findings, which provide additional proof of concept for Alnylam's preclinical AIP treatment ALN-AS1, are based on experiments using siRNAs formulated in lipid nanoparticles and show that such agents are effective at doses as low as 1 mg/kg.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.

Nov
05
Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.